Westmount Partners’s AbbVie ABBV Stock Holding History

Westmount Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.44M	Sell	5,727 -6,457	-53%	-$1.39M	0.32%	70
2026 Q1	$2.65M	Buy	12,184 +7,178	+143%	+$1.59M	0.65%	33
2025 Q4	$1.14M	Sell	5,006 -21	-0.4%	-$4.78K	0.29%	70
2025 Q3	$1.23M	Buy	5,027 +24	+0.5%	+$4.89K	0.32%	68
2025 Q2	$929K	Sell	5,003 -116	-2%	-$21.6K	0.26%	78
2025 Q1	$1.07M	Sell	5,119 -26	-0.5%	-$5.05K	0.33%	67
2024 Q4	$914K	Sell	5,145 -43	-0.8%	-$7.91K	0.28%	71
2024 Q3	$1.02M	Buy	5,188 +16	+0.3%	+$2.99K	0.31%	68
2024 Q2	$881K	Buy	5,172 +152	+3%	+$25.2K	0.29%	71
2024 Q1	$914K	Buy	5,020 +2	+0%	+$345	0.33%	66
2023 Q4	$778K	Sell	5,018 -153	-3%	-$22.3K	0.32%	71
2023 Q3	$771K	Buy	5,171 +458	+10%	+$67.2K	0.34%	70
2023 Q2	$635K	Sell	4,713 -25	-0.5%	-$3.67K	0.28%	79
2023 Q1	$755K	Sell	4,738 -25	-0.5%	-$3.82K	0.35%	65
2022 Q4	$770K	Buy	+4,763	New	+$730K	0.4%	59

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Westmount Partners's ABBV Position: Q2 2026 in Review

Westmount Partners reduced its AbbVie (ABBV) stake by 53% in Q2 2026, selling an estimated $1.39M and leaving 5,727 shares worth $1.44M. The position accounts for 0.32% of the portfolio, ranked #70.

Westmount Partners first reported a position in ABBV in Q4 2022 and has held it in 15 quarters since. The position peaked at $2.65M in Q1 2026. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Westmount Partners held 5,727 shares of AbbVie worth $1.44M as of Q2 2026.
Westmount Partners sold 6,457 AbbVie shares in Q2 2026, an estimated $1.39M.
AbbVie made up 0.32% of Westmount Partners's portfolio in Q2 2026, its #70 holding.
Westmount Partners first reported a position in AbbVie in Q4 2022 and has held it in 15 quarters since.
Westmount Partners's AbbVie position peaked at $2.65M in Q1 2026.
4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Westmount Partners's 13F filing for Q2 2026, filed 7 Jul 2026.